🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT07569302
Starting soon Phase 2

Triggering Ovulation in Normo-responders Using a Modified Dual Trigger Protocol or HCG Trigger

NCT07569302 · tracked via the Priya Life Science Egypt tracker
Phase
Phase 2
Started
2026-06-01
Last updated
2026-05-06

Condition(s) studied

Infertility (IVF Patients)

Investigational drug(s) / intervention(s)

Modified dual triggerHCG

Modified dual trigger: HCG (10000 IU /IM) and triptorelin (0.2 mg/S.C) are administered 36 hours before ovum pickup . Moreover, 0.1mg of triptorelin is administered 24 h prior to ovum pick-up.

HCG: HCG (10000 IU/IM ) is administered 36 hours before ovum pickup.

Study summary

The aim of this randomized controlled study is to compare the efficacy of a modified dual trigger protocol \[a single bolos of HCG combined with two successive doses of a GnRH agonist \] with HCG \[a single bolos administered 36 hours before oocyte retrieval \] in triggering ovulation in normo-responders undergoing ovarian stimulation using the antagonist protocol.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
40 Years
Healthy volunteers
No
Inclusion Criteria: * GnRH antagonist IVF cycle * Normo-responders to induction of ovulation Exclusion Criteria: * Hypogonadotrophic hypogonadism * Endometriosis * History of recurrent abortion

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Bedaya Hospital Giza Giza Governorate

More Bedaya Hospital trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07569302 on ClinicalTrials.gov ↗ ← All trials in Egypt